Nuvectis Pharma (NASDAQ:NVCT) Rating Lowered to “Strong Sell” at Zacks Research

Nuvectis Pharma (NASDAQ:NVCT) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Thursday, Zacks reports.

NVCT has been the topic of several other research reports. Weiss Ratings raised Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Loop Capital set a $40.00 target price on Nuvectis Pharma in a research report on Tuesday, September 1st. Cantor Fitzgerald initiated coverage on shares of Nuvectis Pharma in a research note on Monday, August 24th. They set an “overweight” rating for the company. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of Nuvectis Pharma in a report on Thursday, September 24th. Finally, Wall Street Zen downgraded shares of Nuvectis Pharma from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.25.

Nuvectis Pharma Price Performance

Shares of NVCT traded up $3.15 during mid-day trading on Thursday, reaching $20.91. 257,686 shares of the company’s stock traded hands, compared to its average volume of 171,396. The stock has a market cap of $682.50 million, a P/E ratio of -11.06 and a beta of -0.21. The stock’s 50-day moving average is $20.89 and its two-hundred day moving average is $14.88. Nuvectis Pharma has a 12 month low of $5.55 and a 12 month high of $29.27.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.78). Research analysts predict that Nuvectis Pharma will post -1.30 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NVCT. Oppenheimer & Co. Inc. raised its position in Nuvectis Pharma by 17.3% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 86,291 shares of the company’s stock valued at $1,822,000 after purchasing an additional 12,725 shares in the last quarter. Iridian Asset Management LLC CT increased its stake in shares of Nuvectis Pharma by 2.1% during the third quarter. Iridian Asset Management LLC CT now owns 793,207 shares of the company’s stock valued at $16,753,000 after buying an additional 16,129 shares during the period. Alyeska Investment Group L.P. purchased a new position in shares of Nuvectis Pharma during the second quarter valued at $5,057,000. Stonepine Capital Management LLC bought a new stake in shares of Nuvectis Pharma in the second quarter valued at about $735,600. Finally, Bank of America Corp DE bought a new stake in shares of Nuvectis Pharma in the second quarter valued at about $218,000. Institutional investors own 96.77% of the company’s stock.

Trending Headlines about Nuvectis Pharma

Here are the key news stories impacting Nuvectis Pharma this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $39 price target, well above the stock’s quoted $20.91 price. Nuvectis Pharma analyst coverage
• Negative Sentiment: Zacks Research downgraded NVCT from “hold” to “strong sell,” a bearish change in analyst sentiment that could weigh on shares. TickerReport article
• Negative Sentiment: HC Wainwright lowered its expected earnings per share for Q4 2026 and FY2026–FY2028, signaling larger projected losses. Its FY2026 estimate, for example, moved from a loss of $1.02 to $1.91 per share; the FY2027 and FY2028 loss forecasts also increased. Nuvectis Pharma analyst coverage

About Nuvectis Pharma

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.